跳至主要内容
临床试验/NCT05295134
NCT05295134已完成不适用

A Randomised, Double-Blind, Placebo Controlled, Dose Ranging Study to Investigate the Safety & Efficacy of Candida Rugosa Lipase on Reduction of Serum Triglyceride

BIO-CAT, Inc.2 个研究点 分布在 1 个国家目标入组 39 人开始时间: 2014年3月13日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
BIO-CAT, Inc.
入组人数
39
试验地点
2
主要终点
Safety and tolerability: Adverse events

研究概览

简要总结

The primary objective of this study was to evaluate the safety and tolerability of 3 doses of fungal lipase in the treatment of adults with mildly elevated serum triglycerides. The secondary objective was to assess the efficacy of fungal lipase in reducing serum triglycerides in adults with mildly elevated serum triglycerides.

详细描述

According to the World Health Organization, ischemic heart diseases and stroke were the leading causes of death globally in 2019, accounting for 16% and 11% of the world's total deaths, respectively. The American Heart Association reported in 2020 that approximately 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked (Virani et al). That blockage is typically caused by an accumulation of fatty deposits inside triglycerides (atherosclerosis). Higher levels of serum triglycerides are linked to an increased risk of ischemic stroke in men and women. Researchers tracked 7,579 women and 6,372 men whose triglyceride and cholesterol measurements were taken in the late 1970s. Subjects were followed for up to 33 years. During the follow-up period, 837 women and 837 men developed ischemic stroke. Both men and women had a higher risk of stroke with high levels of triglycerides, in particular triglyceride levels of 5 mmol/L (443 mg/dL or 5.0 mmol/L) or more. These individuals carried four-fold greater stroke risk than those with lower levels (Varbo et al).

Each of the current treatments for hypertriglyceridemia has negative side effects and therefore many individuals that suffer from this condition decline treatment to reduce stroke risk. Oral supplementation with a fungal lipase preparation from Candida cylindracea (formerly rugosa), commonly found in dietary supplements for digestive health, is a candidate strategy to lower triglycerides without side effects.

During digestion, each of lingual, gastric, and pancreatic lipases combine to remove the outer 2 fatty acids from ingested, dietary triglycerides, thus forming monoglycerides and 2 free fatty acids. Following uptake by intestinal enterocytes, the free fatty acids are re-esterified with the monoglycerides to reform triglycerides before release in to the bloodstream. Overconsumption of dietary fats can thus lead to elevated levels of serum triglycerides.

Candida cylindracea (formerly rugosa) lipase, however, hydrolyzes all three fatty acids from dietary triglycerides to release free fatty acids and the glycerol backbone. It is predicted that most of these free fatty acids and glycerol molecules enter the bloodstream without reformation to triglycerides by the major metabolic pathway to reform the triglycerides from monoglycerides. Nonetheless, an alternate metabolic pathway to generate triglycerides from free fatty acids alone does exist in enterocytes.

The investigators tested the hypothesis that fungal lipase-mediated lowering of dietary monoglycerides would lower serum triglyceride levels in a randomized, double-blind, placebo controlled parallel arm clinical trial of 39 subjects with elevated serum triglyceride levels. Subjects were between 18 and 75 years of age, with good general health and mildly elevated serum triglycerides (150 mg/dL to 500 mg/dL, or 1.7 mmol/L to 5.6 mmol/L). The study included 4 study site visits over a 13 to 16 week period (including baseline period).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Be able to give written informed consent
  • Be between 18 and 75 years of age
  • Be in generally good health as determined by the investigator
  • Serum triglyceride levels between 151 mg/dL (1.71 mmol/L) and 499 mg/dL (5.65 mmol/L)

排除标准

  • Are less than 18 and greater than 75 years of age
  • Females are pregnant, lactating or wish to become pregnant during the study
  • Are hypersensitive to any of the components of the test product,
  • Have a significant acute or chronic, unstable and untreated disease or any condition which contraindicates, in the investigator's judgement, entry to the study
  • Have an active gastrointestinal disorder or previous gastrointestinal surgery
  • Have a known family history of hyperlipidemia
  • Having a condition or have taken a medication or supplement that the investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results, including triglyceride lowering medications (e.g., fibrates and statins) and supplements (e.g., plant sterols/stanols, fish oil supplements, and vitamin B complex supplements)
  • Have not made any major dietary changes in the past 3 months
  • History of illicit drug use
  • Subjects who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial
  • Subjects may not be receiving treatment involving experimental drugs
  • If the subject has participated in a recent experimental trial, the trial must have been completed not less than 60 days prior to this study
  • Have a malignant disease or any concomitant end-stage organ disease

结局指标

主要结局

Safety and tolerability: Adverse events

时间窗: 90 days

Self-reported adverse events at Visits 1, 2, and 3

次要结局

  • Safety: Magnesium(90 days)
  • Safety: Urea(90 days)
  • Safety: Total protein(90 days)
  • Safety: Glycated hemoglobin A1C (HbA1C)(90 days)
  • Safety: Albumin(90 days)
  • Safety: Globulin(90 days)
  • Safety: Alanine aminotransferase (ALT)(90 days)
  • Safety: Sodium(90 days)
  • Safety: Total bilirubin(90 days)
  • Safety: Uric acid(90 days)
  • 36-Item Short Form Health Survey (SF-36)(90 days)
  • Safety: Glucose(90 days)
  • The change in blood levels of fasting cholesterol(90 days)
  • The change in levels of fasting serum triglycerides(90 days)
  • Safety: Aspartate aminotransferase (AST)(90 days)
  • Safety: Alkaline phosphatase (ALP)(90 days)
  • Safety: Phosphate(90 days)
  • Safety: Gamma-glutamyl transferase (GGT)(90 days)
  • Safety: Creatinine(90 days)
  • Safety: Potassium(90 days)
  • Safety: Chloride(90 days)
  • Safety: Calcium(90 days)

研究者

发起方
BIO-CAT, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验